BMC psychiatry
January 26, 2024
Laetitia Vanderijst, Felix Hever, Anne Buot et al.
11 citations
A proposed clinical trial will test whether adding psilocybin-assisted therapy to inpatient rehabilitation for severe alcohol use disorder is feasible and effective. In a double-blind, randomized, placebo-controlled phase II trial, 62 participants aged 21–64 will receive either a high dose (30 mg) or an active placebo dose (5 mg) of psilocybin alongside a brief psychotherapy based on acceptance and commitment therapy. The main outcome is the difference in heavy drinking days from baseline to four weeks after hospital discharge. Secondary outcomes include drinking behavior up to six months, mental health symptoms, neuroplasticity, and cognitive mechanisms. The trial is registered as EudraCT 2022-002369-14 and NCT06160232.
Psychiatria Danubina
July 17, 2024
Astrid Kaiserman, Charles Kornreich, Laetitia Vanderijst
1 citation
Psychedelics are being re-evaluated for therapeutic use, with psilocybin-assisted therapy (PAT) showing positive effects on depression and anxiety in patients with life-threatening diseases. PAT appears safe and feasible in clinical settings, with preliminary evidence of immediate and partially sustained improvements in mood symptoms. One trial found no significant difference in efficacy between PAT and selective serotonin reuptake inhibitors. The studies reviewed suggest PAT induces neuroplasticity and may help change inflexible thinking patterns. However, larger, more diverse studies with better controls for expectancy are needed to confirm these promising results.
Research Square (Research Square)
January 4, 2024
Laetitia Vanderijst, Felix Hever, Anne Buot et al.
A proposed double-blind, randomized, placebo-controlled phase II trial will test whether adding psilocybin-assisted therapy to a 4-week inpatient rehabilitation program for severe alcohol use disorder is feasible and clinically effective. Sixty-two participants aged 21–64 years will receive either a high dose (30 mg) or an active placebo dose (5 mg) of psilocybin, both paired with a brief acceptance and commitment therapy intervention. The primary clinical outcome is the change in percentage of heavy drinking days from baseline to four weeks after hospital discharge. Secondary outcomes include drinking behavior up to six months, symptoms of depression and anxiety, neuroplasticity, and changes in neurocognitive systems linked to addiction.